Upperton Capabilities Update April 2026: Fill/Finish

Designing sterile manufacturing facilities to meet Annex 1 expectations requires more than compliance—it demands thoughtful integration of containment, control, and operational flexibility. This overview explores a modern sterile manufacturing environment built to support both aseptic and terminally sterilised drug products for parenteral, nasal, and pulmonary delivery. Attendees gain insight into advanced contamination control strategies and how facility design choices align with the practical needs of small‑ to mid‑sized biotech programs. The session walks through key capabilities, highlighting how scalable infrastructure and specialized expertise support development and manufacturing without unnecessary complexity. Led by senior technical and manufacturing leadership, the tour provides a grounded perspective on how regulatory requirements translate into day‑to‑day operations. For teams evaluating sterile manufacturing partners or planning future capacity, this overview offers a clear look at how purpose‑built facilities can balance compliance, flexibility, and efficiency while supporting diverse delivery formats.